A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Update Il y a 4 ans
Reference: NCT01706926

Woman and Man

Extract

The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid Arthritis (RA).


Inclusion criteria

  • Rheumatoid Arthritis


Links